Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol dose A; Drug: Indacaterol dose B; Drug: Indacaterol dose C; Drug: Indacaterol dose D; Drug: Placebo; Drug: Salmeterol
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Smoking; Smoking Cessation
Interventions: Drug: Nicotine patch; Drug: Nicotine polacrilex; Other: Adherence coaching
Sponsors: University of Wisconsin, Madison; Wisconsin Department of Health and Family Services; Free and Clear, Inc.; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN5401; Drug: insulin detemir; Drug: insulin aspart; Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Pain
Intervention: Other: Acupuncture
Sponsors: University of Washington; Bastyr University
Recruiting - verified March 2010
Conditions: Depression; Major Depressive Disorder
Interventions: Drug: F2695 SR; Drug: Placebo
Sponsor: Forest Laboratories
Recruiting - verified March 2010
Conditions: Obesity; Injury
Interventions: Behavioral: Healthy Eating/Physical Activity; Behavioral: Safety/Injury Prevention
Sponsors: HealthPartners Research Foundation; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Washington; University of Minnesota School of Public Health
Not yet recruiting - verified March 2010
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: gemtuzumab ozogamicin
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified March 2010
Conditions: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Polyneuropathy
Interventions: Drug: SB-509; Other: Saline
Sponsors: Sangamo Biosciences; Juvenile Diabetes Research Foundation
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: NN1250; Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: Indacaterol dose; Drug: Placebo; Drug: Salmeterol
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: CVD
Intervention: Behavioral: Dietician electonic support
Sponsors: Group Health Cooperative; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified February 2010
Condition: Fibromyalgia
Interventions: Drug: Placebo; Drug: Milnacipran
Sponsors: Forest Laboratories; Cypress Bioscience, Inc.
Recruiting - verified February 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Conditions: Arrhythmia; Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Conditions: Arrhythmia; Bradycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With T(15;17)(q22;q12); Adult Acute Myeloid Leukemia With T(16;16)(p13;q22); Adult Acute Myeloid Leukemia With T(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Chronic Phase Chronic Myelogenous Leukemia; De Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Disease, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: plerixafor; Biological: filgrastim; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting - verified February 2010
Condition: Pregnancy
Intervention: Procedure: Induction of Labor
Sponsor: Madigan Army Medical Center
Recruiting - verified February 2010
Condition: Hemangioma
Interventions: Drug: Prednisolone (Corticosteroid); Drug: Propanolol; Drug: Placebo
Sponsor: Seattle Children's Hospital
Not yet recruiting - verified February 2010
Condition: Childhood Cancer
Intervention: Other: Needs Assessment Survey of Adult Childhood Cancer Survivors
Sponsors: St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol; Drug: Placebo
Sponsor: Novartis
Recruiting - verified February 2010
Condition: Urinary Incontinence
Intervention: Device: Athena Pelvic Muscle Trainer
Sponsor: Athena Feminine Technologies, Inc.
Recruiting - verified March 2010
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: interferon beta 1-a; Drug: methylprednisolone; Other: IV placebo; Drug: glatiramer acetate
Sponsors: Biogen Idec; Elan Pharmaceuticals
Not yet recruiting - verified February 2010
Condition: Major Depressive Disorder
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Not yet recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: insulin glargine
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease
Intervention:
Sponsors: University of Washington; Puget Sound Veterans Administration Health Care System; The University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System
Recruiting - verified February 2010
Condition: Perennial Allergic Rhinitis
Intervention: Drug: ciclesonide HFA 160 μg
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Exenatide; Drug: LY2189265; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin UK, Ltd.; Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010
Condition: HIV Infections
Intervention:
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Conditions: Stress Disorders; Combat Disorders; Traumatic Stress Disorders
Interventions: Behavioral: Standard of Care; Behavioral: FOCUS-CI
Sponsors: Henry M. Jackson Foundation for the Advancement of Military Medicine; U.S. Army Medical Research and Materiel Command
Not yet recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified January 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Infantile Hemangioma
Interventions: Drug: Propranolol; Drug: Placebo
Sponsor: Pierre Fabre Dermatology
Recruiting - verified March 2010
Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone methyl (amorphous dispersion)
Sponsor: Reata Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Carboplatin
Sponsor: US Oncology Research
Recruiting - verified February 2010
Condition: Parkinson's Disease
Interventions: Drug: Rasagiline; Drug: Placebo
Sponsor: Teva Pharmaceutical Industries
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: NN1250; Drug: sitagliptin
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Acute Myelogenous Leukemia
Intervention: Drug: PR104
Sponsor: Proacta, Incorporated
Recruiting - verified February 2010
Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Conditions: Barrett Syndrome; Barrett's Syndrome; Barrett's Esophagus; Barrett Esophagus; Adenocarcinoma
Interventions: Device: Standard endoscopic treatment of BE; Device: pCLE guided endoscopic treatment of BE
Sponsors: Mauna Kea Technologies; Cellvizio Inc.
Recruiting - verified March 2010
Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control
Interventions: Drug: Dapagliflozin; Drug: Placebo
Sponsors: AstraZeneca; Bristol-Myers Squibb
Recruiting - verified March 2010
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Interventions: Drug: Canagliflozin on background standard of care for diabetes; Drug: Placebo on background standard of care for diabetes
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; George Institute, Sydney, Australia
Recruiting - verified February 2010
Condition: Metastatic Melanoma
Interventions: Drug: Cisplatin; Biological: ALT-801
Sponsors: Altor Bioscience Corporation; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: insulin glargine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR); Drug: 3-4 commercially available antiretroviral drugs
Sponsor: Myriad Pharmaceuticals
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type II
Intervention: Other: Metabolic Testing
Sponsors: University of Washington; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010
Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: rifampin; Drug: midazolam; Drug: ketoconazole; Drug: brentuximab vedotin
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Condition: Castleman's Disease
Interventions: Other: Placebo; Drug: CNTO 328
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir (SCH 503034); Drug: erythropoietin; Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Osteoarthritis Knee Pain
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Healthy
Intervention: Procedure: Blood draw
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Combivent Respimat; Drug: Combivent CFC-MDI; Drug: Atrovent HFA + Albuterol HFA
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Intervention: Drug: STA 9090
Sponsor: Synta Pharmaceuticals Corp.
Recruiting - verified February 2010
Conditions: Carcinoma, Renal Cell; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-75
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Back Pain; Chronic Low Back Pain; Internal Disc Disruption; Degenerative Disc Disease
Interventions: Biological: Biostat System; Drug: Sodium Chloride Injection
Sponsor: Spinal Restoration, Inc.
Recruiting - verified March 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GW642444 Inhalation Powder; Drug: FF/GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Active Rheumatoid Arthritis
Intervention: Drug: SBI-087
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Onychomycosis
Interventions: Drug: IDP-108; Drug: Vehicle
Sponsor: Dow Pharmaceutical Sciences
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875 6.25 mg; Drug: TAK-875 25 mg; Drug: TAK-875 50 mg; Drug: TAK-875 100 mg; Drug: TAK-875 200 mg; Drug: Glimepiride 2 mg or 4mg; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010
Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: ACT-128800; Drug: Placebo
Sponsor: Actelion
Recruiting - verified February 2010
Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Acute Migraine With or Without Aura
Intervention: Drug: rizatriptan benzoate
Sponsor: Merck
Recruiting - verified March 2010
Condition: Back Pain
Interventions: Drug: REGN475/SAR164877; Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified March 2010
Condition: Chronic Kidney Disease
Interventions: Drug: Paricalcitol; Drug: Placebo
Sponsors: University of Washington; Abbott
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Keryx / AOI Pharmaceuticals, Inc.; Dana-Farber Cancer Institute
Recruiting - verified March 2010
Conditions: Graft-Versus-Host Disease; Immune System Disorders
Interventions: Drug: Mycophenolate Mofetil; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Newtwork (BMT CTN)
Recruiting - verified March 2010
Condition: Acute Migraine With or Without Aura in Children and Adolescents.
Interventions: Drug: rizatriptan benzoate; Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Acute Coronary Syndrome; Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease
Interventions: Drug: Darapladib 160 mg; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Haemophilus Influenzae Type B Related Disease; Pneumonia; Meningitis; Cellulitis; Osteomyelitis; Epiglottis
Interventions: Biological: InfanrixTM; Biological: GSK Biologicals' Haemophilus inluenzae type b vaccine (GSK 208108); Biological: ActHIBTM; Biological: PentacelTM; Biological: PediarixTM; Biological: PrevnarTM; Biological: RotarixTM; Biological: EngerixTM-B
Sponsor: GlaxoSmithKline
Not yet recruiting - verified March 2010
Condition: Sinusitis
Intervention:
Sponsor: University of Washington
Recruiting - verified March 2010
Condition: Cystitis, Interstitial
Interventions: Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Biological: Tanezumab; Other: Placebo
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: extended-release guanfacine hydrochloride; Drug: placebo; Drug: extended-release guanfacine hydrochloride
Sponsor: Shire Pharmaceutical Development
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Recruiting - verified March 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: flibanserin; Drug: placebo; Drug: placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Sexual Dysfunctions, Psychological
Interventions: Drug: Flibanserin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Posttraumatic Stress Disorder (PTSD)
Interventions: Drug: orvepitant; Other: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Psoriasis
Interventions: Drug: Etanercept ONLY; Drug: Methotrexate and Etanercept
Sponsors: Amgen; Immunex Corporation
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Linagliptin; Drug: Linagliptin; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Contraception
Interventions: Drug: LNG20; Drug: Mirena
Sponsor: Medicines360
Recruiting - verified February 2010
Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip
Interventions: Other: Tanezumab 2.5 mg; Other: Tanezumab 5 mg; Other: Tanezumab 10 mg
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo; Biological: Certolizumab pegol
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Influenza
Intervention: Biological: Inactivated H1N1 Vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2009
Conditions: Pain; Diabetic Neuropathy, Painful
Interventions: Drug: Placebo; Drug: JNJ-42160443
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Influenza
Intervention: Biological: Inactivated Influenza H1N1 vaccine
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2010
Conditions: Stage IV Breast Cancer; Central Nervous System Involvement/Metastases; Leptomeningeal Metastases; Recurrent Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: methotrexate; Drug: liposomal cytarabine; Other: quality-of-life assessment; Other: questionnaire administration
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified February 2010
Condition: Legg-Calve Perthes Disease
Intervention: Drug: Aristospan 20mg
Sponsor: Seattle Children's Hospital
Recruiting - verified March 2010
Condition: Lymphoblastic Leukemia, Acute, Childhood
Intervention: Drug: Clofarabine incorporated into a 5-drug regimen
Sponsor: Genzyme
Recruiting - verified October 2009
Condition: Coronary Artery Disease
Interventions: Drug: Apadenoson; Drug: Adenosine
Sponsors: PGxHealth, LLC; PPD
Recruiting - verified March 2010
Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Condition: Acute Myeloid Leukemia
Intervention: Drug: Compound AC220
Sponsor: Ambit Biosciences Corporation
Recruiting - verified March 2010
Condition: Metastatic Prostate Cancer
Intervention:
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified February 2010
Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: oxycodone; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Thyroid Neoplasm
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Fluticasone propionate/salmeterol combination product; Drug: Salmeterol; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Congenital FXIII Deficiency
Intervention: Drug: recombinant factor XIII
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: insulin glargine + preprandial lispro insulin; Biological: albiglutide + insulin glargine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Chemotherapy + figitumumab; Drug: Chemotherapy
Sponsor: Pfizer
Not yet recruiting - verified March 2010
Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
Condition: Severe Nodular Acne
Intervention: Drug: CIP-Isotretinoin and Isotretinoin
Sponsor: Cipher Pharmaceuticals Inc.
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type II
Interventions: Drug: Placebo; Drug: Dutogliptin
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Condition: Sinusitis
Intervention:
Sponsor: University of Washington
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepiride; Drug: JNJ-28431754
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Conditions: Adenocarcinoma; Advanced Breast Cancer; Advanced Metastatic Breast Cancer; ErbB2+; Her2+; Invasive Breast Cancer; Metastatic ErbB2
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Biological: LY2439821; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: Erlotinib; Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: LY2216684
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Systemic Lupus Erythematosus
Interventions: Drug: placebo; Drug: rontalizumab
Sponsor: Genentech
Recruiting - verified February 2010
Condition: Hepatitis C, Chronic
Interventions: Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: RO5190591; Drug: Placebo; Drug: Placebo; Drug: Pegasys; Drug: Copegus
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Dyslipidemia
Interventions: Drug: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT); Drug: Comparator: Extended-release niacin (ERN); Drug: Comparator: Placebo to ERN/LRPT
Sponsor: Merck
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: TOK-001; Drug: TOK-001; Drug: TOK-001
Sponsor: Tokai Pharmaceuticals
Recruiting - verified February 2010
Conditions: Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma
Interventions: Drug: XL184; Drug: temozolomide; Drug: temozolomide; Radiation: Radiation Therapy; Drug: temozolomide
Sponsor: Exelixis
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Seasonal Influenza; Cough; Sore Throat; Nasal Congestion; Myalgia; Headache; Fatigue
Interventions: Drug: Peramivir; Drug: Peramivir
Sponsors: BioCryst Pharmaceuticals; Department of Health and Human Services
Recruiting - verified March 2010
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: warfarin; Drug: placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Duke University
Recruiting - verified February 2010
Conditions: Breast Cancer; Hot Flashes; Menopausal Symptoms; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: flaxseed; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Partial Epilepsies
Intervention: Drug: Lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Autism Spectrum Disorder
Intervention: Behavioral: Joint Attention Intervention
Sponsors: Health Resources and Services Administration (HRSA); University of California, Los Angeles; University of Washington; University of Michigan; Florida State University; Johns Hopkins University
Recruiting - verified November 2009
Condition: Hematologic Malignancies
Interventions: Drug: PF-04449913; Drug: dasatinib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Hepatitis C
Intervention: Drug: Infergen with or without ribavirin
Sponsor: Three Rivers Pharmaceuticals
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: AMG 827 70 mg; Drug: AMG 827 140 mg; Drug: AMG 827 210 mg; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Conditions: Multiple Sclerosis; Spinal Cord Injury
Interventions: Behavioral: Motivational interviewing; Behavioral: Education
Sponsor: University of Washington
Recruiting - verified February 2010
Condition: Diabetes Mellitus, Type II
Interventions: Drug: Dutogliptin; Drug: Placebo
Sponsors: Forest Laboratories; Phenomix
Recruiting - verified February 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cervical Disc Disease
Intervention: Device: Zero-P PEEK
Sponsor: Synthes Spine
Recruiting - verified March 2010
Condition: Chronic Hepatitis C Infection (HCV)
Interventions: Drug: vaniprevir (MK7009); Drug: Comparator: Pegylated Interferon (Peg-IFN); Drug: Comparator: Ribavirin (RBV)
Sponsor: Merck
Recruiting - verified March 2010
Condition: Multiple Sclerosis
Interventions: Behavioral: Self-management intervention; Behavioral: Education
Sponsor: University of Washington
Recruiting - verified February 2010
Conditions: Hindfoot Arthrodesis; Hindfoot Pathologies
Intervention:
Sponsors: AO Clinical Investigation and Documentation; Synthes Inc.
Recruiting - verified March 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Asthma
Interventions: Drug: QMF149 Twisthaler®; Drug: Mometasone Twisthaler®
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Intervention: Drug: Dimebon
Sponsors: Pfizer; Medivation, Inc.
Recruiting - verified March 2010
Condition: Postmenopausal Osteoporosis
Interventions: Drug: Ibandronate; Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Neoplasms; Unresectable Metastatic Cutaneous Melanoma
Intervention: Biological: Immunotherapeutic GSK2132231A
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Vc-RCHOP; Drug: RCHOP
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Metastatic Colorectal Cancer
Intervention: Drug: EZN-2208, Cetuximab and Irinotecan
Sponsor: Enzon Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Adalimumab
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: Placebo; Drug: OROS MPH
Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010
Conditions: Brain and Central Nervous System Tumors; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Severe Vasospasm
Intervention: Drug: Cervical Sympathetic Block (bupivicaine, clonidine)
Sponsor: University of Washington
Recruiting - verified February 2010
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Degenerative Disc Disease
Interventions: Device: XL TDR; Other: Lumbar fusion surgery
Sponsor: NuVasive
Recruiting - verified February 2010
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride; Drug: Placebo
Sponsor: Amicus Therapeutics
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate plus leuprolide acetate plus prednisone; Drug: leuprolide acetate
Sponsor: Cougar Biotechnology, Inc.
Recruiting - verified March 2010
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: LY2216684; Drug: Methylphenidate; Drug: Placebo (tablet); Drug: Placebo (capsule)
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Leukemia-relapsed or Refractory
Interventions: Drug: GSK1120212; Drug: GSK1120212
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified March 2010
Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: Other: biologic sample preservation procedure
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Variola Major (Smallpox)
Interventions: Biological: IMVAMUNE® (liquid, intradermal); Biological: IMVAMUNE® (lyophilized); Biological: IMVAMUNE® (liquid, subcutaneous)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2010
Conditions: Graft Versus Host Disease; Leukemia; Myelodysplastic Syndromes
Interventions: Drug: Fludarabine Phosphate; Drug: Tacrolimus; Drug: Thiotepa; Radiation: Total-Body Irradiation (TBI); Device: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Sponsors: Yale University; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010
Conditions: Hereditary Angioedema; C1 Esterase Inhibitor Deficiency
Intervention: Biological: C1 inhibitor (human)
Sponsor: ViroPharma
Recruiting - verified August 2009
Condition: Overactive Bladder
Interventions: Drug: Fesoterodine; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Influenza
Interventions: Biological: A/Anhui/05; Biological: MF-59; Drug: Placebo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified December 2009
Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsor: Celgene Corporation
Recruiting - verified February 2010
Condition: Colorectal Cancer
Intervention: Drug: olaparib
Sponsors: AstraZeneca; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified February 2010
Conditions: Atrial Fibrillation; Arrhythmia; Stroke Prevention; Mortality
Interventions: Device: Left atrial ablation; Drug: Rate or Rhythm Control Therapy
Sponsors: Mayo Clinic; National Heart, Lung, and Blood Institute (NHLBI); Duke University; St. Jude Medical; Biosense Webster, Inc.
Recruiting - verified February 2010
Condition: Contrast Media
Intervention: Drug: Eovist (Primovist, BAY86-4873)
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Arformoterol; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Condition: Chemotherapy Induced Anemia
Interventions: Biological: Biological: ACE-011; Drug: Placebo
Sponsors: Acceleron Pharma, Inc.; Celgene Corporation
Recruiting - verified March 2010
Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Irritable Bowel Syndrome
Interventions: Behavioral: Usual Care; Behavioral: Comprehensive Self-Management
Sponsors: University of Washington; National Institute of Nursing Research (NINR)
Recruiting - verified March 2010
Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (lisdexamfetamine dimesylate); Drug: placebo matching SPD489 (lisdexamfetamine dimesylate)
Sponsor: Shire Pharmaceutical Development
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Interventions: Drug: LY2062430; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Neuroblastoma
Interventions: Genetic: loss of heterozygosity analysis; Other: cytology specimen collection procedure; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Dyslipidaemia
Interventions: Drug: Niaspan; Drug: GSK256073; Drug: GSK256073; Drug: GSK256073; Drug: Placebo; Drug: GSK256073; Drug: GSK256073
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Conditions: Herpes Zoster; Shingles
Interventions: Drug: valacyclovir; Drug: FV-100; Drug: FV-100; Drug: Valacyclovir placebo; Drug: FV-100 placebo
Sponsor: Inhibitex
Recruiting - verified February 2010
Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Other: biologic sample preservation procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Intervention: Other: cryopreservation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Other: biologic sample preservation procedure; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: Sipuleucel-T
Sponsor: Dendreon
Recruiting - verified March 2010
Condition: Alzheimer Disease
Intervention: Drug: Placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Glioblastoma Multiforme
Intervention: Drug: Azixa
Sponsor: Myriad Pharmaceuticals
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: Nonbiologic DMARDs of investigator's choice
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Nonneoplastic Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sunitinib malate; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Interventions: Drug: BMS-708163; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified December 2009
Condition: Smoking Cessation
Interventions: Behavioral: Quitline Service + 10 automated monitoring calls; Behavioral: Quitline service + 20 automated monitoring calls
Sponsors: Indiana University; Free and Clear, Inc.; Kaiser Foundation Hospitals, Center for Health Research; University of Washington
Not yet recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: docetaxel; Drug: doxorubicin; Drug: cyclophosphamide; Drug: cyclophosphamide; Drug: pegfilgrastim
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; US Oncology Research
Recruiting - verified March 2010
Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine succinate sustained release Dose A; Drug: Placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Coronary Artery Chronic Total Occlusion
Intervention: Device: Recanalization of a coronary chronic total occlusion
Sponsor: BridgePoint Medical
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: systemic chemotherapy; Procedure: axillary lymph node dissection; Procedure: neoadjuvant therapy; Procedure: sentinel lymph node biopsy; Procedure: therapeutic conventional surgery; Procedure: ultrasound imaging
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: CNTO 3649; Placebo
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Depression
Interventions: Drug: orvepitant; Other: placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: ixabepilone
Sponsor: Eisai Inc.
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Bosutinib; Drug: Letrozole
Sponsor: Wyeth
Recruiting - verified March 2010
Conditions: Idiopathic Pulmonary Fibrosis; Pulmonary Hypertension
Intervention: Drug: Ambrisentan or placebo
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Conditions: Traumatic Brain Injury; Depression
Interventions: Behavioral: In-person Cognitive Behavioral Therapy; Behavioral: Telephone Cognitive Behavioral Therapy
Sponsors: University of Washington; National Institutes of Health (NIH); U.S. Department of Education
Recruiting - verified February 2010
Condition: Low Back Pain
Interventions: Biological: Tanezumab 20 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 10 mg IV; Drug: Placebo for naproxen; Biological: Tanezumab 5 mg IV; Drug: Placebo for naproxen; Biological: Placebo for tanezumab; Drug: Naproxen; Biological: Placebo for tanezumab; Drug: Placebo for naproxen
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Conditions: Cardiovascular Disease; Type 2 Diabetes Mellitus
Interventions: Drug: pioglitazone; Drug: placebo; Dietary Supplement: vitamin D; Dietary Supplement: placebo; Drug: rosiglitazone
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: bortezomib; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: tetomilast; Drug: placebo
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2010
Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass
Interventions: Drug: Acadesine; Drug: Normal Saline
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Supracondylar Humerus Fracture
Intervention: Other: Occupational therapy
Sponsor: Seattle Children's Hospital
Recruiting - verified March 2010
Condition: Rhesus D Genotype
Intervention:
Sponsors: Sequenom, Inc.; NAFTNet
Recruiting - verified March 2010
Condition: Heart Failure
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: thiotepa; Drug: vincristine sulfate; Drug: vorinostat; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Procedure: adjuvant therapy
Sponsors: Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditions: Pregnancy; Pregnant Women
Intervention:
Sponsors: University of Washington; Stanford University
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Other: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Abraxis BioScience Inc.; University of Arizona
Recruiting - verified August 2009
Condition: Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Chemotherapeutic Agent Toxicity; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: paclitaxel; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Insomnia; Attention Deficit Hyperactivity Disorder
Intervention: Drug: eszopiclone
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: CP 690,550; Drug: CP-690,550; Other: Placebo; Other: Placebo; Biological: Biologic TNFi
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Aspergillosis
Intervention: Other: No Intervention
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Impetigo; Secondarily-infected Traumatic Lesions
Interventions: Drug: Linezolid; Drug: Retpamulin Ointment, 1%
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Bipolar Depression
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2010
Conditions: Herpes Zoster; HIV Infections
Interventions: Biological: Zoster Vaccine Live; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Adult AIDS Clinical Trials Group; Merck
Recruiting - verified May 2009
Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: fluoxetine; Drug: duloxetine; Drug: duloxetine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Colorectal Cancer (CRC)
Interventions: Drug: Irinotecan; Drug: 5-Fluorouracil (bolus); Drug: 5-Fluorouracil (infusional); Drug: Leucovorin calcium; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab Placebo (saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Cystic Fibrosis
Intervention: Other: Early Intervention
Sponsors: University of Washington; Cystic Fibrosis Foundation
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab placebo (ie saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: B-Cell Lymphoma; B-Cell Leukemia
Intervention: Drug: PCI-32765
Sponsor: Pharmacyclics
Recruiting - verified July 2009
Condition: Major Depressive Disorder
Interventions: Drug: duloxetine; Drug: Placebo; Drug: fluoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: bevacizumab; Biological: rituximab; Drug: fludarabine phosphate
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
Sponsor: United Therapeutics
Not yet recruiting - verified February 2009
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified December 2009
Condition: Essential Hypertension
Interventions: Drug: TAK-491 and chlorthalidone; Drug: TAK-491 and chlorthalidone; Drug: Olmesartan medoxomil-hydrochlorothiazide
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Bipolar Depression
Interventions: Drug: Olanzapine Fluoxetine Combination; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Conditions: Anemia; Leukemia; Myelodysplastic Syndromes
Interventions: Biological: epoetin alfa; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Mucocutaneous Lymph Node Syndrome; Kawasaki Disease
Interventions: Drug: Etanercept; Drug: Placebo
Sponsors: Seattle Children's Hospital; FDA Office of Orphan Products Development; Amgen
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cytarabine; Drug: idarubicin; Drug: pravastatin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Neoplasms
Interventions: Drug: LY2603618; Drug: Gemcitabine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors
Intervention: Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Smoking Cessation; Smoking; Tobacco Cessation
Interventions: Biological: NicVAX vaccine; Biological: Placebo vaccine
Sponsors: Nabi Biopharmaceuticals; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2010
Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer; Duke University
Recruiting - verified October 2009
Conditions: Adrenocortical Carcinoma; Kidney Cancer; Liver Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Attention Deficit Disorder With Hyperactivity
Intervention: Other: CATMH intervention
Sponsor: Seattle Children's Hospital
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Cetuximab; Drug: Paclitaxel; Drug: Carboplatin; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: Accelerated Community Oncology Research Network; ImClone LLC; Advanced Clinical Trial Solutions, LLC
Recruiting - verified February 2010
Conditions: Arthritis; Osteoarthritis
Interventions: Biological: tanezumab 10 mg; Biological: tanezumab 5 mg; Drug: naproxen; Other: placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: aflibercept; Drug: topotecan hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Human Immunodeficiency Virus-1
Interventions: Drug: maraviroc; Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Non-small Cell
Intervention: Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Osteoarthritis
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Osteoarthritis; Arthritis
Interventions: Drug: NSAID; Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Drug: NSAID; Biological: tanezumab; Drug: NSAID
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: methotrexate; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Intervention: Drug: Rivaroxaban; Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified February 2010
Condition: Asthma
Interventions: Drug: Levalbuterol; Drug: Levalbuterol UDV TID; Drug: Placebo
Sponsor: Sepracor, Inc.
Recruiting - verified February 2010
Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: Folic Acid; Drug: BIBF1120 placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Idiopathic Restless Legs Syndrome
Interventions: Drug: placebo and pregabalin; Drug: pramipexol; Drug: pramipexol; Drug: Pregabalin; Drug: pramipexol; Drug: pramipexol
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Cystic Fibrosis
Interventions: Drug: Ataluren (PTC124); Drug: Placebo
Sponsors: PTC Therapeutics; Genzyme; Cystic Fibrosis Foundation
Recruiting - verified March 2010
Condition: Fibromyalgia
Interventions: Drug: Sodium Oxybate; Drug: Sodium Oxybate & Tablet; Drug: Sodium Oxybate & Tablets; Drug: Sodium Oxybate Oral Solution (6 grams)
Sponsor: Jazz Pharmaceuticals
Recruiting - verified March 2010
Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsor: Abbott
Recruiting - verified January 2010
Conditions: Atherosclerosis; Cardiovascular Disease; Coronary Heart Disease; CV Risk
Interventions: Drug: Darapladib; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Cancer
Interventions: Other: internet-based intervention; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: fatigue assessment and management; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified August 2009
Condition: Postoperative Pain
Intervention: Other: Psychophysical testing, questionnaires, and genetics
Sponsor: University of Washington
Recruiting - verified March 2010
Condition: Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Other: active surveillance
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: sirolimus; Drug: tacrolimus; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Psoriasis
Interventions: Drug: etanercept / placebo; Drug: placebo / etanercept
Sponsor: Amgen
Recruiting - verified February 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Biological: natural killer cell therapy; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified August 2009
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Comparator: Placebo
Sponsors: Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified March 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: ixabepilone; Drug: paclitaxel; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Crohn's Disease
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Ulcerative Colitis
Interventions: Drug: vedolizumab; Other: Placebo
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Psychosocial Effects of Cancer and Its Treatment; Sarcoma
Interventions: Other: educational intervention; Other: informational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: standard follow-up care
Sponsors: Tufts Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Advanced Breast Cancer
Interventions: Drug: Bosutinib; Drug: Exemestane
Sponsor: Wyeth
Recruiting - verified February 2010
Conditions: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic
Interventions: Drug: maraviroc; Drug: etravirine
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: ridaforolimus (MK8669); Drug: Comparator: Placebo; Drug: open-label ridaforolimus (MK8669)
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Conditions: Breast Cancer; Chemotherapeutic Agent Toxicity; Fatigue; Neuropathy; Neurotoxicity
Interventions: Dietary Supplement: acetyl-L-carnitine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Other: clinical observation; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); Bacchus Vascular; BSN Medical Inc; Genentech; MEDRAD Interventional/Possis; Mid America Heart Institute; Society of Interventional Radiology Foundation; VasCore at Massachusetts General Hospital
Recruiting - verified February 2010
Condition: Chronic Migraine
Interventions: Drug: propranolol LA; Drug: topiramate; Drug: placebo
Sponsors: The EMMES Corporation; National Institute of Neurological Disorders and Stroke (NINDS); Ortho-McNeil Janssen Scientific Affairs, LLC; CRC Operations Center
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Crohn's Disease
Intervention: Drug: Ustekinumab; CNTO1275
Sponsor: Centocor, Inc.
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Rhinitis; Allergic Conjunctivitis
Interventions: Biological: 1.5 Amb a 1-U; Biological: 6 Amb a 1-U; Biological: 12 Amb a 1-U; Biological: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: rituximab; Biological: tositumomab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Radiation: iodine I 131 tositumomab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: IMC-A12 in combination with androgen deprivation therapy
Sponsors: Fred Hutchinson Cancer Research Center; ImClone LLC
Recruiting - verified February 2010
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: ambrisentan or sugar pill
Sponsor: Gilead Sciences
Recruiting - verified March 2010
Condition: Healthy
Interventions: Biological: MEDI-559; Other: Placebo; Biological: MEDI-559
Sponsor: MedImmune LLC
Recruiting - verified March 2010
Condition: Acromegaly
Interventions: Drug: Octreotide Implant; Drug: Sandostatin LAR Depot
Sponsor: Endo Pharmaceuticals Solutions Inc.
Recruiting - verified February 2010
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Lymphoma; Multiple Myeloma; Leukemia, Myelomonocytic, Chronic
Intervention: Drug: azacitidine
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Condition: Optic Neuropathy, Ischemic
Intervention:
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified February 2010
Conditions: Chronic Sinusitis; Facial Pain Disorder; Depression
Interventions: Drug: escitalopram; Drug: placebo
Sponsors: University of Washington; National Institutes of Health (NIH); Forest Laboratories
Recruiting - verified March 2010
Condition: Osteosarcoma
Interventions: Drug: AZD0530; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration; AstraZeneca
Recruiting - verified February 2010
Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Neoplasms
Intervention: Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Arthritis; Osteoarthritis; Osteoarthritis, Hip
Interventions: Biological: tanezumab; Biological: tanezumab; Biological: tanezumab; Biological: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: zoledronic acid; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Papillomavirus Infections
Intervention:
Sponsors: University of Washington; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Conditions: Fibrosis; Kidney Failure; Renal Insufficiency
Intervention: Procedure: Lab sample drawn for serum chemistry at baseline visit
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: ASA404 in combination with docetaxel; Drug: Placebo in combination with docetaxel
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Conditions: Migraine; Migraine With Aura; Migraine Without Aura
Intervention: Drug: ramelteon
Sponsors: Swedish Medical Center; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Other: survey administration; Procedure: assessment of therapy complications; Procedure: long-term screening; Procedure: study of high risk factors
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Biological: IMC-1121B; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2189265; Drug: Sitagliptin 100mg, 24 months; Drug: Placebo solution; Drug: Placebo tablet, 6 months; Drug: Placebo tablet, 24 months; Drug: Sitagliptin 100 mg, 18 months
Sponsors: Eli Lilly and Company; United BioSource Corporation; Tessella Inc.; Berry Consultants
Recruiting - verified March 2010
Conditions: Renal Cell Carcinoma; Non-small Cell Lung Cancer; Malignant Melanoma; Epithelial Ovarian Cancer; Colorectal Adenocarcinoma
Intervention: Biological: MDX-1105
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Glioma
Interventions: Drug: TMZ; Drug: BIBW 2992 plus TMZ; Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Fibromyalgia
Intervention: Drug: Treatment for Fibromyalgia
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Drug: vandetanib; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Fatigue; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous Condition; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Dietary Supplement: American ginseng; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Depression; Depressive Symptoms; Anxiety; Stress Disorders, Post-Traumatic; ICU Hospitalization; Care and Treatment in ICU
Interventions: Behavioral: Facilitator-Based intervention; Behavioral: Usual Care
Sponsors: University of Washington; National Institute of Nursing Research (NINR)
Recruiting - verified March 2010
Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Adenocarcinoma, Renal Cell; Nephroid Carcinoma; Carcinoma, Hypernephroid
Interventions: Drug: bevacizumab, RAD001(Everolimus); Drug: bevacizumab, interferon alfa-2a
Sponsors: Novartis Pharmaceuticals; Roche Pharma AG
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Biological: Sipuleucel-T; Biological: Sipuleucel-T; Biological: Sipuleucel-T
Sponsor: Dendreon
Recruiting - verified February 2010
Condition: Patent Ductus Arteriosus
Intervention: Device: AMPLATZER Duct Occluder II
Sponsor: AGA Medical Corporation
Recruiting - verified March 2010
Conditions: Diphtheria; Pertussis; Tetanus
Interventions: Drug: Placebo; Biological: Tdap
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsor: Agennix
Recruiting - verified March 2010
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: sunitinib malate; Drug: sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: atomoxetine hydrochloride; Drug: placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; US Oncology Research
Recruiting - verified February 2010
Condition: Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Conditions: Lumbar Spinal Stenosis; Neurogenic Intermittent Claudication
Interventions: Device: Superion™ Interspinous Spacer; Device: X-STOP® IPD® Device
Sponsor: VertiFlex, Incorporated
Recruiting - verified February 2010
Conditions: Breast Cancer; Osteoporosis
Interventions: Drug: exemestane; Other: biologic sample preservation procedure; Other: physiologic testing; Procedure: dual x-ray absorptometry
Sponsor: NCIC Clinical Trials Group
Recruiting - verified June 2009
Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: anti-VEGF small molecule PTC299; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: biopsy
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI); PTC Therapeutics Incorporated
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Advanced Cancer; Chronic Obstructive Pulmonary Disease (COPD); Restrictive Lung Disease; Congestive Heart Failure; End Stage Liver Disease
Intervention: Behavioral: Training Program Intervention
Sponsors: University of Washington; National Institute of Nursing Research (NINR)
Recruiting - verified February 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: cixutumumab; Drug: capecitabine; Drug: lapatinib ditosylate
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Thromboembolism
Interventions: Drug: Dabigatran etexilate; Drug: Warfarin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Dyslipidemias; Coronary Heart Disease; Kidney Disease
Interventions: Drug: ABT-335; Drug: Rosuvastatin; Drug: Placebo
Sponsors: Abbott; AstraZeneca
Recruiting - verified February 2010
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Prevention of Venous Thromboembolism; Cancer
Interventions: Drug: AVE5026; Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: SC-PEG E. coli L-asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: bortezomib; Drug: cytarabine; Drug: etoposide phosphate; Drug: idarubicin
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Euvolemic Hyponatremia
Interventions: Drug: lixivaptan; Drug: placebo
Sponsors: CardioKine Inc.; Cardiokine Biopharma, LLC; Biogen Idec
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: azacitidine; Drug: gemtuzumab ozogamicin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Interventions: Drug: montelukast sodium; Other: flow cytometry; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2008
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Condition: Atrial Septal Defect
Intervention: Device: AMPLATZER Septal Occluder
Sponsor: AGA Medical Corporation
Recruiting - verified January 2009
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Pulmonary Fibrosis
Interventions: Drug: Prednisone; Drug: Azathioprine; Drug: N-acetylcysteine (NAC); Drug: Placebo
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010
Condition: Coronary Heart Disease
Interventions: Drug: dalceptrapib; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Venous Thrombosis
Interventions: Drug: Enoxaparin; Drug: warfarin; Drug: Placebo for apixaban; Drug: Placebo for enoxaparin; Drug: Placebo for warfarin; Drug: apixaban
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified October 2009
Condition: Urinary Tract Infection
Intervention:
Sponsors: University of Washington; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010
Condition: High Risk Stage III Melanoma
Interventions: Drug: ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Ocular Safety
Intervention: Drug: Observational Study
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Venous Thrombosis
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Pfizer
Recruiting - verified February 2010
Condition: Primary Immunodeficiency Disease
Intervention: Biological: Flebogamma 5% DIF
Sponsor: Grifols Biologicals Inc.
Recruiting - verified March 2010
Condition: Cystic Fibrosis
Interventions: Drug: inhaled mannitol; Drug: Placebo comparator
Sponsors: Pharmaxis; ethica Clinical Research Inc.
Recruiting - verified March 2010
Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsor: Gentium SpA
Recruiting - verified February 2010
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Biological: aflibercept
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Conditions: Liver Cancer; Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dasatinib; Other: pharmacological study
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: TRU-016 (anti-CD37 protein therapeutic)
Sponsor: Trubion Pharmaceuticals
Recruiting - verified March 2010
Condition: Dental Anxiety
Interventions: Behavioral: Computer Assisted Relaxation Learning; Behavioral: Pamphlet
Sponsors: University of Washington; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Hypoactive Sexual Desire Disorder
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsor: BioSante Pharmaceuticals
Recruiting - verified February 2010
Conditions: Attention Deficit Hyperactivity Disorder; Dyslexia
Interventions: Drug: Atomoxetine; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Conditions: Crohn's Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
Interventions: Biological: infliximab; Drug: conventional systemic agents; Biological: Biological therapies other than infliximab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: melphalan; Drug: prednisone; Drug: thalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: letrozole; Drug: tamoxifen citrate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: capecitabine; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Osteosarcoma; Sarcoma, Ewing's; Peripheral Neuroectodermal Tumor
Interventions: Drug: SCH 717454 (19D12); Drug: SCH 717454 (19D12)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Major Depressive Disorder; Dysthymia; Spinal Cord Injuries
Interventions: Drug: venlafaxine XR; Drug: placebo
Sponsors: University of Washington; University of Michigan; Rehabilitation Institute of Chicago; University of Alabama at Birmingham; Baylor Institute for Rehabilitation, Dallas
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: Liquid Certolizumab pegol; Drug: Liquid Certolizumab pegol; Other: Placebo; Drug: Methotrexate
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Breast Tumors
Intervention: Drug: Trabectedin; ET 743; Yondelis
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar S.A.
Recruiting - verified February 2010
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Venous Thromboembolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: docetaxel; Drug: pertuzumab; Drug: placebo; Drug: trastuzumab
Sponsors: Genentech; Roche Pharma AG
Recruiting - verified March 2010
Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: memantine hydrochloride; Other: placebo; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: docetaxel; Drug: paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Alzheimer's Disease
Interventions: Drug: PF-04494700; Drug: PF-04494700; Drug: Placebo
Sponsors: Pfizer; Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010
Condition: Osteoarthritis
Interventions: Drug: SD-6010; Drug: SD-6010; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Colorectal Neoplasms; Neoplasm Metastasis
Interventions: Drug: Aflibercept (AVE0005); Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Venous Thromboembolism
Interventions: Drug: dabigatran etexilate 150 mg BID; Drug: matching placebo BID
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib (Tykerb); Drug: pazopanib (GW786034); Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Procedure: conventional surgery; Radiation: stereotactic body radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Anal Cancer; Precancerous Condition
Interventions: Drug: cidofovir; Genetic: DNA methylation analysis; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Procedure: biopsy; Procedure: histopathologic examination
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: testosterone gel; Drug: placebo gel
Sponsors: University of Washington; National Institute on Aging (NIA); Solvay Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Intervention: Drug: asparaginase-Erwinia
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Glioma
Intervention: Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: PTSD; Sleep Disorders
Interventions: Drug: prazosin; Other: placebo
Sponsor: Department of Veterans Affairs
Recruiting - verified January 2010
Condition: Aspergillosis
Interventions: Drug: voriconazole; Drug: anidulafungin; Drug: voriconazole
Sponsors: Pfizer; Mycoses Study Group
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: docetaxel; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Atherosclerosis; Myocardial Ischemia; Myocardial Infarction
Interventions: Drug: SCH 530348; Drug: Placebo
Sponsors: Schering-Plough; Duke University
Recruiting - verified March 2010
Conditions: Genital Herpes; HIV Infections
Interventions: Drug: valacyclovir; Drug: acyclovir
Sponsors: University of Washington; GlaxoSmithKline
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: IL-2; Drug: sirolimus
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network
Recruiting - verified February 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Rotigotine; Other: Placebo
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Epilepsy
Interventions: Drug: lacosamide; Drug: lacosamide
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: dutasteride; Other: placebo
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified August 2009
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Drug: conventional systemic agents; Biological: infliximab; Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab
Sponsor: Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: bortezomib, thalidomide, and dexamethasone (VTD); Drug: bortezomib and dexamethasone (VD); Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010
Condition: Substance-Related Disorders
Interventions: Drug: midazolam(drug), digoxin (drug); Drug: Bupropion (drug); Drug: Methadone (drug)
Sponsor: University of Washington
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Lung Neoplasms
Intervention: Drug: Pemetrexed
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Melanoma
Intervention: Drug: Ipilimumab
Sponsor: Bristol-Myers Squibb
Available - verified March 2010
Condition: Leukemia
Interventions: Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin; Other: clinical observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: duloxetine hydrochloride; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: beclomethasone dipropionate; Drug: methotrexate; Drug: tacrolimus; Other: placebo
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Ulcerative Colitis
Interventions: Biological: golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Neoplasms
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsor: OncoGenex Technologies
Recruiting - verified February 2010
Condition: Ulcerative Colitis
Interventions: Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Golimumab, placebo; Biological: Placebo
Sponsors: Centocor, Inc.; Schering-Plough
Recruiting - verified February 2010
Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Recruiting - verified February 2010
Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2009
Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: fluorescence in situ hybridization; Genetic: polymorphism analysis; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Heart Decompensation
Interventions: Drug: Placebo; Drug: Nesiritide
Sponsor: Scios, Inc.
Recruiting - verified February 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: Temsirolimus; Drug: Sorafenib
Sponsor: Wyeth
Recruiting - verified February 2010
Conditions: Neurotoxicity; Pain; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: ketamine/amitriptyline NP-H cream; Other: placebo
Sponsors: University of Rochester; National Cancer Institute (NCI)
Recruiting - verified August 2009
Condition: Cytomegalovirus Infections
Interventions: Drug: Placebo; Drug: Valganciclovir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Conditions: Chronic Obstructive Pulmonary Disease (COPD); Heart Failure
Interventions: Behavioral: Exercise adherence; Behavioral: Self-management- prevention of illness; Behavioral: Self-management of illness
Sponsor: Department of Veterans Affairs
Recruiting - verified February 2010
Condition: Colorectal Neoplasms
Interventions: Drug: bevacizumab; Drug: AG-013726; Drug: AG-013736 (axitinib)
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 706; Drug: placebo
Sponsors: Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: denileukin diftitox; Biological: rituximab; Other: flow cytometry; Other: immunoenzyme technique; Other: laboratory biomarker analysis
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Secondary Myelofibrosis
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: methotrexate; Drug: tacrolimus; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Pulmonary Embolism
Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939); Drug: Enoxaparin followed by VKA
Sponsors: Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: erlotinib hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Cognitive/Functional Effects; Leukemia; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Genetic: microarray analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: cognitive assessment; Procedure: diffusion tensor imaging; Procedure: management of therapy complications; Procedure: psychosocial assessment and care
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Anemia; Chronic Kidney Disease; Kidney Disease
Interventions: Drug: darbepoetin alfa QW; Drug: darbepoetin alfa Q2W
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Thoracic Aortic Aneurysms
Intervention: Device: Relay Thoracic Stent-Graft
Sponsor: Bolton Medical
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin hydrochloride; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Systemic Lupus Erythematosus
Interventions: Drug: steroids (prednisone or prednisolone) + MMF; Drug: abatacept; Drug: abatacept
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Lung Cancer
Intervention: Drug: IPI-504
Sponsor: Infinity Pharmaceuticals
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Conditions: Lung Cancer; Adenocarcinoma
Intervention: Drug: sunitinib
Sponsors: Swedish Medical Center; Pfizer
Recruiting - verified March 2010
Condition: HIV Infections
Intervention: Drug: maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: dasatinib; Genetic: gene expression analysis; Genetic: mutation analysis; Other: immunohistochemistry staining method; Other: immunologic technique; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study; Procedure: biopsy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Cancer; Colon Cancer; Colorectal Cancer; Metastatic Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: FOLFIRI - Panitumumab; Drug: FOLFIRI - Bevacizumab
Sponsor: Amgen
Recruiting - verified February 2010
Condition: Arthritis, Rheumatoid
Intervention: Other: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: Breast Cancer; Metastatic Cancer
Intervention: Drug: dasatinib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Cancer
Intervention: Drug: lithium carbonate
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Benign Prostatic Hyperplasia (BPH)
Intervention: Device: Prolieve® Thermodilatation System
Sponsor: Boston Scientific Corporation
Recruiting - verified February 2010
Condition: Aged
Intervention:
Sponsor: Department of Veterans Affairs
Recruiting - verified March 2010
Condition: Interstitial Cystitis
Intervention: Drug: pentosan polysulfate sodium
Sponsor: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Recruiting - verified February 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Secondary Myelofibrosis
Interventions: Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel; Procedure: positron emission tomography; Procedure: radionuclide imaging; Radiation: carbon-11 acetate; Radiation: fludeoxyglucose F 18
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: liposomal cytarabine; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Influenza
Intervention: Drug: oseltamivir (Tamiflu®)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Brain Metastases From Non-small Cell Lung Cancer
Intervention: Drug: HYCAMTIN, oral capsules
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: lapatinib ditosylate; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Supraventricular Tachycardia in Infants
Intervention: Drug: digoxin and propranolol
Sponsors: University of British Columbia; The Hospital for Sick Children; University of Utah
Recruiting - verified February 2010
Condition: Breast Cancer
Intervention: Drug: chemotherapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Graft Versus Host Disease; Leukemia
Interventions: Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: sorafenib tosylate; Drug: temsirolimus
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Osteoarthritis
Interventions: Drug: Celecoxib; Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: mitoxantrone hydrochloride
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: methotrexate; Other: laboratory biomarker analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: thioguanine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: vitamin D; Drug: calcium gluconate; Drug: zoledronic acid; Radiation: samarium Sm 153 lexidronam pentasodium; Radiation: strontium chloride Sr 89
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein; Other: flow cytometry; Other: immunohistochemistry staining method; Other: immunological diagnostic method; Other: laboratory biomarker analysis; Procedure: biopsy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Urethritis
Interventions: Drug: Azithromycin; Drug: Doxycycline
Sponsors: University of Washington; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Leukemia
Intervention: Drug: lenalidomide
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: eltrombopag olamine (SB-497115-GR)
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; The Cleveland Clinic
Recruiting - verified March 2010
Conditions: Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: clinical observation; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Ovarian Cancer; Merkel Cell Carcinoma; SCLC
Intervention: Drug: BB-10901
Sponsor: ImmunoGen, Inc.
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified December 2009
Conditions: Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: sorafenib tosylate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Retinoblastoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Non Hodgkin Lymphoma
Interventions: Drug: enzastaurin; Drug: placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Drug: sunitinib malate; Other: placebo
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine ditartrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified March 2010
Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Epilepsy; Epilepsy, Generalized; Epilepsy, Complex Partial; Epilepsies, Partial; Seizures
Interventions: Drug: Diazepam; Drug: Placebo
Sponsor: King Pharmaceuticals Research and Development
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Pulmonary Hypertension
Interventions: Drug: bosentan; Drug: placebo
Sponsor: Actelion
Recruiting - verified March 2010
Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: rituximab; Drug: fenretinide
Sponsors: University of Washington; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Head and Neck Cancer; Radiation Toxicity
Interventions: Drug: amifostine trihydrate; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Arrhythmia; Bradycardia; Heart Failure; Sinus Tachycardia
Intervention:
Sponsor: Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Behavioral: compliance monitoring; Drug: mercaptopurine; Drug: methotrexate; Other: study of socioeconomic and demographic variables
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydro
All Locations ... United States » ... Washington 
